Leone Asset Management Acquires ALM Research and Development BELLEAIR BLUFFS, FL / ACCESSWIRE / January 10, 2017 / Today, Leone Asset Management (PINK SHEETS: LEON) announces they have acquired ALM Research & Development, Inc., an innovative company specializing in the formulation of innovative nutraceutical and cosmeceutical products. James Price, CEO of Leone Asset Management stated, “This is simply an amazing acquisition for Leone Asset. Steve Kushner and ALM R&D have created a game changing technology that greatly enhances the absorption and efficacy of virtually thousands of compounds that are used in nutraceutical and cosmeceutical products. Clinical research was performed at a major independent research facility in the Northeast, where the delivery technology was studied, using a proprietary 3-D skin tissue model, for permeation of, and retention of transdermal compounds within the human skin tissue. The results of the studies were extremely encouraging. We are currently using the technology in our subsidiary Go Epic Health’s flagship product Cholesterade® and the increase in efficacy and overall results have been outstanding. We intend to commit a lot of time and effort in creating new products for our Go Epic Health offering as well as improving other products existing in the marketplace today under exclusive licensing agreements.” About Leone Asset Management Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness in the U.S., Technology Development in India and Infrastructure development, agriculture management, and mineral exploration and export in Africa. For additional information, visit: www.leoneasset.com. About ALM Research and Development ALM Research & Development is a company specializing in the formulation of innovative nutriceutical and cosmeceutical products for both the consumer and professional marketplace and has had several products marketed through major national chains. A major focus of ALM for the past 6 years has been in creating a more efficient method to deliver compounds to the body. As a result, ALM has created a novel platform delivery technology, which is fully patent-pending. It has been clinically demonstrated to increase permeation and duration of activity of compounds through transdermal delivery as well as enhance active compound uptake and bioavailability when applied orally. The technology not only holds multiple compounds and transports them into the body with unprecedented efficiency, but also has a major positive impact on the surrounding physiology that is the target of delivery for the active ingredients. This technology is in use with a number of topical products in the medical/aesthetic field. For further information, please visit www.leoneasset.com. About Go Epic Health